The Centers for Disease Control (hereafter referred to as CDC) announced that recently there were 4 newly confirmed cases of monkeypox, consisting of 2 domestic cases and
2 imported cases, all male aged in their 20s to 40s, with onset after mid‑May, the onset
most had not been vaccinated against monkeypox before onset, and sought medical care as rashes, fever, chills and general fatigue gradually appeared on the genitals, limbs, trunk, etc.
fatigue and other symptoms, were examined by physicians who suspected monkeypox, collected samples and reported, leading to confirmation; genetic typing confirmed that among them, 1
imported case's viral strain was type Ib, marking the second domestic case of monkeypox Ib imported case in the country,
the others were infected with type II.
The CDC noted that the global monkeypox outbreak continues; in May of this year, a total of 32 countries/regions reported 1,142
confirmed cases, of which 63.9% of cases originated from Africa, with a total of 3 deaths, a case‑fatality rate of 0.3%, and the distribution of cases was primarily in Madagascar, China, France, Australia and Germany.
Since 2022, the monkeypox outbreak has caused
large‑scale community transmission worldwide, with a cumulative total reported by 144 countries of over 185,000 confirmed monkeypox cases and 509
deaths, primarily distributed across the Americas and Africa.
The CDC explained that the threat of cross‑border transmission of the global monkeypox Ib (Clade Ib) virus has increased since January 2024,
with 63 countries or regions having reported confirmed Ib cases. In the past six weeks (May 4 – June 14), Asian regions have seen sporadic cases including
China (1 case) and Thailand (2 cases); in Africa, cases were reported mainly in Madagascar, Kenya, Guinea, South
Sudan, Cameroon and the Democratic Republic of the Congo. Additionally, Spain and Thailand continue to report community transmission of the Ib type,
and Norway has also reported its first Ib case; according to statistics, the fatality rate of Ib is slightly higher but comparable to II, and disease severity is related to the individual's immune status.
The CDC stated that domestically, as of July 6 this year, there have been a cumulative total of 19 confirmed monkeypox cases (15 domestic and 4 imported), all of which are young adult males, aged between 20‑50 years, and have been listed as a Category 2 statutory infectious disease since June 2022.
Since the outbreak, a total of 535 cases have been confirmed (496 locally transmitted and 39 imported), and cases have been reported in the north, central, and southern regions. Epidemiological investigations found that all confirmed individuals had engaged in unsafe sexual behavior, and nearly 90% had not received the Mpox vaccine. This year's case count is lower than the same periods in 2024 and 2025 (24 and 21 cases, respectively).
The CDC points out that as of the end of June this year, about 110,000 people have received at least one dose of the Mpox vaccine, and more than 78,000 have completed the two‑dose series, indicating that nearly 30%, about 31,000 people, have not yet received the second dose. The CDC reminds that the incubation period of Mpox can be up to 21 days, and some cases can transmit Mpox to others 1 to 4 days before symptom onset. Vaccination against Mpox is currently the most effective method and can simultaneously prevent infection by both clade I and clade II viruses. Receiving only one dose provides roughly 40% to 80% protection, while completing two doses raises protection to about 90%. A total of 312 partner medical institutions nationwide offer publicly funded Mpox vaccination services to eligible individuals, including those who have engaged in risk behaviors in the past year (e.g., multiple sexual partners, sex workers, sexual activity in commercial venues, etc.); those with a history of sexually transmitted infections; or whose sexual partners have any of the aforementioned conditions. Eligible persons should promptly complete the two‑dose publicly funded Mpox vaccination. Information on publicly funded vaccination sites can be found on the CDC’s website under the Mpox section / Mpox vaccine / Mpox vaccine vaccination service partner medical institutions ( https://gov.tw/3SG ). For those who do not meet the criteria for publicly funded Mpox vaccination, if a physician assesses a genuine exposure risk, they may receive the Mpox vaccine at their own expense at any of the eight contract travel‑medicine hospitals nationwide; related information is available on the CDC’s website under International Travel and Health / Travel Medicine Clinics.
Source: Centers for Disease Control
Data compiled: Sensory Management Office
